A research team at the Technical University of Munich (TUM) has developed a method to predict early-stage kidney damage ...

Announcing a new article publication for BIO Integration journal. Bladder cancer (BLCA) is one of the most common malignancies and the second most frequent urogenital tract tumor.

Cretostimogene grenadenorepvec is an investigational oncolytic immunotherapy that is being studied for the treatment of bladder cancer, particularly non-muscle invasive bladder cancer (NMIBC) that is ...

Data from the phase 3 BOND-003 trial (NCT04452591), presented at the 2025 American Urological Association Annual Meeting, demonstrated that intravesical cretostimogene grenadenorepvec (CG0070) is a ...

Lightweight, high-precision AI model effectively overcomes two major barriers to AI deployment in bladder cancer care: Low detection rates for difficult-to-identify lesions. Prohibitive computational ...

Some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab, ...

ImmunityBio, Inc. faces stock decline amid fundraising and market selloff. Click to read more on the long-term potential of ...

In a study from Dr. Zlotta’s group published in 2025 in the Journal of Urology, 1 they suggest that better tools are needed to minimize interobserver variability in pathological grading. This is ...

The ongoing phase 2b SunRISe-1 study is assessing TAR-200 intravesical gemcitabine delivery in patients with BCG-unresponsive high-risk NMIBC.

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Some of these cancerous mutations in DNA are inherited, while others arise from errors that occur as a cell divides.

A new report on cancer in the US shows a steady decline in overall deaths from 2001 through 2022. The rate of diagnoses among ...